38 - Traitement de la maladie de Parkinson

J J Poza, J F Marti-Massó, A Lopez de Munain, Drugs inducing or aggravating parkinsonism: a review. Therapie. ,vol. 51, pp. 568- 577 ,(1996)

N. Quinn, Drug treatment of Parkinson's disease. BMJ. ,vol. 310, pp. 575- 579 ,(1995) , 10.1136/BMJ.310.6979.575

Jean-Louis Montastruc, Jean-Michel Senard, Olivier Rascol, Pharmacologie des médicaments antiparkinsoniens Médecine thérapeutique. ,vol. 3, pp. 197- 201 ,(1997)

Ira Shoulson, Neuroprotective clinical strategies for Parkinson's disease. Annals of Neurology. ,vol. 32, ,(1992) , 10.1002/ANA.410320725

A Lledó, Dopamine agonists: the treatment for Parkinson's disease in the XXI century? Parkinsonism & Related Disorders. ,vol. 7, pp. 51- 58 ,(2000) , 10.1016/S1353-8020(00)00038-9

M.B. Stern, The early treatment of Parkinson's disease: levodopa, dopamine agonists or both Parkinsonism & Related Disorders. ,vol. 7, pp. 27- 33 ,(2000) , 10.1016/S1353-8020(00)00045-6

E. Ch. Wolters, G. Tissingh, P. L.M. Bergmans, M. A. Kuiper, Dopamine agonists in Parkinson's disease Neurology. ,vol. 45, ,(1995) , 10.1212/WNL.45.3_SUPPL_3.S28

Wei-Dong Le, Joseph Jankovic, Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs & Aging. ,vol. 18, pp. 389- 396 ,(2001) , 10.2165/00002512-200118060-00001

J. K. Tsui, S. Ross, K. Poulin, J. Douglas, D. Postnikoff, S. Calne, W. Woodward, D. B. Calne, The effect of dietary protein on the efficacy of L-dopa: a double-blind study. Neurology. ,vol. 39, pp. 549- 549 ,(1989) , 10.1212/WNL.39.4.549

Frédéric Assal, Laurent Spahr, Antoine Hadengue, Laura Rubbici-Brandt, Pierre R Burkhard, Tolcapone and fulminant hepatitis The Lancet. ,vol. 352, pp. 958- 958 ,(1998) , 10.1016/S0140-6736(05)61511-5